{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:17:45Z","timestamp":1790720265201,"version":"4.1.0"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2022,3,7]],"date-time":"2022-03-07T00:00:00Z","timestamp":1646611200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002341","name":"Academy of Finland","doi-asserted-by":"publisher","award":["315969"],"award-info":[{"award-number":["315969"]}],"id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002341","name":"Academy of Finland","doi-asserted-by":"publisher","award":["320107"],"award-info":[{"award-number":["320107"]}],"id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002341","name":"Academy of Finland","doi-asserted-by":"publisher","award":["345326"],"award-info":[{"award-number":["345326"]}],"id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Finnish Ministry of Social Affairs"},{"DOI":"10.13039\/100008723","name":"Finnish Medical Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008723","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,5,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>It has remained unclear what factors relate to primary nonadherence to antipsychotic treatment and whether specific agents and routes of administration differ in how patients adhere to them. We collected electronic prescriptions and their dispensings from the Finnish electronic prescription database for 29 956 patients with schizophrenia prescribed antipsychotics via electronic prescription during 2015\u20132016. We defined primary nonadherence as being prescribed an antipsychotic, which was not dispensed from the pharmacy within one year from prescription. Using logistic regression, we analyzed whether several sociodemographic and clinical factors related to nonadherence. We found that 31.7% (N = 9506) of the patients demonstrated primary nonadherence to any of their prescribed antipsychotics. We found that young age (OR = 1.77, 95%CI = 1.59\u20131.96), concomitant benzodiazepines (OR = 1.47, 95%CI = 1.40\u20131.55) and mood stabilizers (OR = 1.29, 95%CI = 1.21\u20131.36), substance abuse (OR = 1.26 95%CI = 1.19\u20131.35), previous suicide attempt (OR = 1.21, 95%CI = 1.11\u20131.31), diabetes (OR = 1.15, 95%CI = 1.06\u20131.25), asthma\/COPD (OR = 1.14, 95%CI = 1.04\u20131.25), and cardiovascular disease (OR = 1.12, 95%CI = 1.05\u20131.19), were related to primary nonadherence to antipsychotic treatment. Patients using clozapine showed the lowest nonadherence (4.77%, 95%CI = 4.66\u20134.89), and patients using long-acting injectables were more adherent to treatment (7.27%, 95%CI = 6.85\u20137.71) when compared to respective oral agents (10.26%, 95%CI = 10.02\u201310.49). These results suggest that selection between different pharmacological agents and routes of administration while taking into account patients\u2019 concomitant medications (benzodiazepines in particular) and comorbidities play a key role in primary nonadherence to antipsychotic treatment.<\/jats:p>","DOI":"10.1093\/schbul\/sbac014","type":"journal-article","created":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T07:09:22Z","timestamp":1643267362000},"page":"655-663","source":"Crossref","is-referenced-by-count":74,"title":["Primary Nonadherence to Antipsychotic Treatment Among Persons with Schizophrenia"],"prefix":"10.1093","volume":"48","author":[{"given":"Johannes","family":"Lieslehto","sequence":"first","affiliation":[{"name":"University of Eastern Finland, Department of Forensic Psychiatry, Niuvanniemi Hospital, Kuopio, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jari","family":"Tiihonen","sequence":"additional","affiliation":[{"name":"University of Eastern Finland, Department of Forensic Psychiatry, Niuvanniemi Hospital, Kuopio, Finland"},{"name":"Karolinska Institutet, Department of Clinical Neuroscience, Stockholm, Sweden"},{"name":"Center for Psychiatry Research, Stockholm City Council, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7244-145X","authenticated-orcid":false,"given":"Markku","family":"L\u00e4hteenvuo","sequence":"additional","affiliation":[{"name":"University of Eastern Finland, Department of Forensic Psychiatry, Niuvanniemi Hospital, Kuopio, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antti","family":"Tanskanen","sequence":"additional","affiliation":[{"name":"University of Eastern Finland, Department of Forensic Psychiatry, Niuvanniemi Hospital, Kuopio, Finland"},{"name":"Karolinska Institutet, Department of Clinical Neuroscience, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi","family":"Taipale","sequence":"additional","affiliation":[{"name":"University of Eastern Finland, Department of Forensic Psychiatry, Niuvanniemi Hospital, Kuopio, Finland"},{"name":"Karolinska Institutet, Department of Clinical Neuroscience, Stockholm, Sweden"},{"name":"University of Eastern Finland, School of Pharmacy, Kuopio, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,3,7]]},"reference":[{"issue":"3","key":"2022050707564690000_CIT0001","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1001\/archpsyc.56.3.241","article-title":"Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder","volume":"56","author":"Robinson","year":"1999","journal-title":"Arch Gen Psychiatry."},{"issue":"3","key":"2022050707564690000_CIT0002","doi-asserted-by":"crossref","first-page":"453","DOI":"10.4088\/JCP.v67n0317","article-title":"Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care","volume":"67","author":"Ascher-Svanum","year":"2006","journal-title":"J Clin Psychiatry."},{"issue":"2-3","key":"2022050707564690000_CIT0003","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.psychres.2009.05.004","article-title":"Predictors and clinical consequences of nonadherence with antipsychotic medication in the outpatient treatment of schizophrenia","volume":"176","author":"Novick","year":"2010","journal-title":"Psychiatry Res."},{"issue":"5","key":"2022050707564690000_CIT0004","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1002\/pds.837","article-title":"Increased suicide attempt rate among patients interrupting use of atypical antipsychotics","volume":"12","author":"Herings","year":"2003","journal-title":"Pharmacoepidemiol Drug Saf."},{"issue":"11","key":"2022050707564690000_CIT0005","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1016\/j.clinthera.2006.11.002","article-title":"Compliance with refilling prescriptions for atypical antipsychotic agents and its association with the risks for hospitalization, suicide, and death in patients with schizophrenia in Quebec and Saskatchewan: a retrospective database study","volume":"28","author":"Ward","year":"2006","journal-title":"Clin Ther."},{"issue":"6","key":"2022050707564690000_CIT0006","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1176\/appi.ajp.2015.15050618","article-title":"Mortality and cumulative exposure to antipsychotics, antidepressants, and benzodiazepines in patients with schizophrenia: an observational follow-up study","volume":"173","author":"Tiihonen","year":"2016","journal-title":"Am J Psychiatry."},{"issue":"3","key":"2022050707564690000_CIT0007","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.eurpsy.2013.03.002","article-title":"Improved quality of life over one year is associated with improved adherence in patients with schizophrenia","volume":"29","author":"Hayhurst","year":"2014","journal-title":"Eur Psychiatry."},{"issue":"2","key":"2022050707564690000_CIT0008","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1176\/ps.49.2.196","article-title":"Compliance with medication regimens for mental and physical disorders","volume":"49","author":"Cramer","year":"1998","journal-title":"Psychiatr Serv."},{"issue":"10","key":"2022050707564690000_CIT0009","doi-asserted-by":"crossref","first-page":"892","DOI":"10.4088\/JCP.v63n1007","article-title":"Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature","volume":"63","author":"Lacro","year":"2002","journal-title":"J Clin Psychiatry."},{"key":"2022050707564690000_CIT0010","first-page":"1","article-title":"The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness","volume":"70","author":"Velligan","year":"20092009","journal-title":"J Clin Psychiatry."},{"issue":"7","key":"2022050707564690000_CIT0011","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1017\/S0033291703008328","article-title":"How often do patients with psychosis fail to adhere to treatment programmes? A systematic review","volume":"33","author":"Nos\u00e9","year":"2003","journal-title":"Psychol Med."},{"issue":"4","key":"2022050707564690000_CIT0012","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1093\/schbul\/sbj075","article-title":"Defining and assessing adherence to oral antipsychotics: a review of the literature","volume":"32","author":"Velligan","year":"2006","journal-title":"Schizophr Bull."},{"issue":"5","key":"2022050707564690000_CIT0013","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1176\/appi.ps.54.5.665","article-title":"Psychopharmacology: perspectives on medication adherence and atypical antipsychotic medications","volume":"54","author":"Velligan","year":"2003","journal-title":"PS."},{"issue":"10202","key":"2022050707564690000_CIT0014","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","article-title":"Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis","volume":"394","author":"Huhn","year":"2019","journal-title":"Lancet"},{"issue":"5","key":"2022050707564690000_CIT0015","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1177\/2042098618756261","article-title":"Safety of antipsychotics for the treatment of schizophrenia: a focus on the adverse effects of clozapine","volume":"9","author":"De Berardis","year":"2018","journal-title":"Ther Adv Drug Safety"},{"issue":"2","key":"2022050707564690000_CIT0016","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/oxfordjournals.schbul.a007076","article-title":"Poor antipsychotic adherence among patients with schizophrenia: medication and patient factors","volume":"30","author":"Valenstein","year":"2004","journal-title":"Schizophr Bull."},{"issue":"7","key":"2022050707564690000_CIT0017","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1001\/jamapsychiatry.2017.1322","article-title":"Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29 823 patients with schizophrenia","volume":"74","author":"Tiihonen","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"2022050707564690000_CIT0018","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.schres.2017.12.010","article-title":"Antipsychotics and mortality in a nationwide cohort of 29,823 patients with schizophrenia","volume":"197","author":"Taipale","year":"2018","journal-title":"Schizophr Res."},{"key":"2022050707564690000_CIT0019","doi-asserted-by":"crossref","first-page":"217047","DOI":"10.1155\/2015\/217047","article-title":"Medication adherence measures: an overview","volume":"2015","author":"Lam","year":"2015","journal-title":"Biomed Res Int."},{"key":"2022050707564690000_CIT0020","doi-asserted-by":"crossref","DOI":"10.1201\/9780429292859","volume-title":"Data Mining with R: Learning with Case Studies","author":"Torgo","year":"2011"},{"key":"2022050707564690000_CIT0021","doi-asserted-by":"crossref","DOI":"10.1007\/978-0-387-98141-3","volume-title":"ggplot2: elegant graphics for data analysis","author":"Wickham","year":"2009"},{"issue":"1","key":"2022050707564690000_CIT0022","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J Royal Stat Soc Ser B (Methodol)."},{"issue":"13","key":"2022050707564690000_CIT0023","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1017\/S0033291717000873","article-title":"Antipsychotic medication and long-term mortality risk in patients with schizophrenia; a systematic review and meta-analysis","volume":"47","author":"Vermeulen","year":"2017","journal-title":"Psychol Med."},{"issue":"1","key":"2022050707564690000_CIT0024","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/wps.20699","article-title":"20-year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20)","volume":"19","author":"Taipale","year":"2020","journal-title":"World Psychiatry"},{"issue":"6","key":"2022050707564690000_CIT0025","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/eip.12412","article-title":"Age at onset and the outcomes of schizophrenia: a systematic review and meta-analysis","volume":"11","author":"Immonen","year":"2017","journal-title":"Early Interv Psychiatry"},{"issue":"Suppl","key":"2022050707564690000_CIT0026","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1016\/S0920-9964(98)00161-3","article-title":"Dual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcomes","volume":"35","author":"Dixon","year":"1999","journal-title":"Schizophr Res."},{"issue":"1","key":"2022050707564690000_CIT0027","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1600-0447.2012.01911.x","article-title":"Predictors of medication adherence in patients with schizophrenia and bipolar disorder","volume":"127","author":"J\u00f3nsd\u00f3ttir","year":"2013","journal-title":"Acta Psychiatr Scand."},{"issue":"4","key":"2022050707564690000_CIT0028","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.cpr.2006.09.004","article-title":"Reasons for increased substance use in psychosis","volume":"27","author":"Gregg","year":"2007","journal-title":"Clin Psychol Rev."},{"key":"2022050707564690000_CIT0029","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1177\/1359786810385490","article-title":"Suicide and schizophrenia: a systematic review of rates and risk factors","volume":"24","author":"Hor","year":"2010","journal-title":"J Psychopharmacol."},{"issue":"2-3","key":"2022050707564690000_CIT0030","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0920-9964(00)00003-7","article-title":"Risk factors for suicide in young people suffering from schizophrenia: a long-term follow-up study","volume":"47","author":"De Hert","year":"2001","journal-title":"Schizophr Res."},{"issue":"6","key":"2022050707564690000_CIT0031","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/acps.12913","article-title":"Mortality in schizophrenia: 30-year nationwide follow-up study","volume":"138","author":"Tanskanen","year":"2018","journal-title":"Acta Psychiatr Scand."},{"key":"2022050707564690000_CIT0032","first-page":"100","article-title":"Do antipsychotic medications decrease the risk of suicide in patients with schizophrenia?","volume":"60","author":"Palmer","year":"1999","journal-title":"J Clin Psychiatry."},{"issue":"1","key":"2022050707564690000_CIT0033","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1093\/schbul\/sbab087","article-title":"Antipsychotics use is associated with greater adherence to cardiometabolic medications in patients with schizophrenia: results from a nationwide, within-subject design study","volume":"48","author":"Solmi","year":"2022","journal-title":"Schizophr Bull."},{"issue":"10","key":"2022050707564690000_CIT0034","doi-asserted-by":"crossref","first-page":"e2019029","DOI":"10.1001\/jamanetworkopen.2020.19029","article-title":"Incidence of and characteristics associated with long-term benzodiazepine use in Finland","volume":"3","author":"Taipale","year":"2020","journal-title":"JAMA Network Open"},{"issue":"10","key":"2022050707564690000_CIT0035","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1176\/ps.2008.59.10.1207","article-title":"Dosing frequency and adherence to antipsychotic medications","volume":"59","author":"Pfeiffer","year":"2008","journal-title":"Psychiatr Serv."},{"issue":"2","key":"2022050707564690000_CIT0036","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1093\/oxfordjournals.schbul.a006943","article-title":"Predictors of risk of nonadherence in outpatients with schizophrenia and other psychotic disorders","volume":"28","author":"Weiss","year":"2002","journal-title":"Schizophr Bull."},{"issue":"4","key":"2022050707564690000_CIT0037","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1093\/schbul\/sbaa002","article-title":"Using open questions to understand 650 people\u2019s experiences with antipsychotic drugs","volume":"46","author":"Read","year":"2020","journal-title":"Schizophr Bull."},{"issue":"1","key":"2022050707564690000_CIT0038","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1001\/archpsyc.1974.01760130049008","article-title":"Why do schizophrenic patients refuse to take their drugs?","volume":"31","author":"Putten T","year":"1974","journal-title":"Arch Gen Psychiatry."},{"issue":"2-3","key":"2022050707564690000_CIT0039","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0920-9964(01)00312-7","article-title":"Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder","volume":"57","author":"Robinson","year":"2002","journal-title":"Schizophr Res."},{"issue":"3","key":"2022050707564690000_CIT0040","doi-asserted-by":"crossref","first-page":"354","DOI":"10.4088\/JCP.v65n0311","article-title":"Adherence to conventional and atypical antipsychotics after hospital discharge","volume":"65","author":"Diaz","year":"2004","journal-title":"J Clin Psychiatry."},{"issue":"3","key":"2022050707564690000_CIT0041","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/wps.20060","article-title":"Nonadherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies","volume":"12","author":"Kane","year":"2013","journal-title":"World Psychiatry"}],"container-title":["Schizophrenia Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/schizophreniabulletin\/article-pdf\/48\/3\/655\/43614186\/sbac014.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/schizophreniabulletin\/article-pdf\/48\/3\/655\/43614186\/sbac014.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,17]],"date-time":"2024-09-17T07:45:22Z","timestamp":1726559122000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/schizophreniabulletin\/article\/48\/3\/655\/6543159"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,7]]},"references-count":41,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,3,7]]},"published-print":{"date-parts":[[2022,5,7]]}},"URL":"https:\/\/doi.org\/10.1093\/schbul\/sbac014","relation":{},"ISSN":["0586-7614","1745-1701"],"issn-type":[{"value":"0586-7614","type":"print"},{"value":"1745-1701","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,5,1]]},"published":{"date-parts":[[2022,3,7]]}}}